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Abstract 
RIPK1 is involved in signalling from TNF 
and TLR family receptors. After receptor 
ligation, RIPK1 not only modulates activation 
of both canonical and NIK-dependent NF-!B, 
but also regulates caspase-8 activation and 
cell death. Although over-expression of 
RIPK1 can cause caspase-8 dependent cell 
death, when RIPK1
-/-
 cells are exposed to 
TNF and low doses of cycloheximide, they die 
more readily than wild type cells, indicating 
RIPK1 has pro-survival as well as pro-
apoptotic activities (1,2). To determine how 
RIPK1 promotes cell survival, we compared 
wild type and RIPK1
-/-
 cells treated with TNF. 
Although TRAF2 levels remained constant in 
TNF-treated wild type cells, TNF stimulation 
of RIPK1
-/-
 cells caused TRAF2 and cIAP1 to 
be rapidly degraded by the proteasome, 
which led to an increase in NIK levels. This 
resulted in processing of p100 NF-!B2 to p52, 
a decrease in levels of cFLIPL , and activation 
of caspase-8, culminating in cell death. 
Therefore, the pro-survival effect of RIPK1 is 
mediated by stabilisation of TRAF2 and 
cIAP1. 
 
Introduction 
In mouse embryonic fibroblasts (MEFs), TNFR1 
signalling is mediated by binding of the adaptor 
protein TRADD to its cytoplasmic domains. 
TRADD then recruits TRAF2 and RIPK1. 
TRAF2 binds to cIAP1 and cIAP2, which 
mediate ubiquitylation of RIPK1 (3-5). A series 
of ubiquitylation and phosphorylation events 
follow, leading to activation of TAK1, p65/RelA 
NF-!B and JNK (6-8). When pro-survival 
signals mediated by NF-!B are blocked, for 
example by deletion of genes for p65/RelA, or 
addition of the translation inhibitor 
cycloheximide, ligation of TNFR1 results in 
recruitment of FADD, binding and activation of 
caspase-8, and apoptosis. 
Ligation-induced recruitment of RIPK1 to 
TNFR1 was thought to be necessary for 
activation of the IKK complex that 
phosphorylates IkB prior to its ubiquitylation by 
SCF
BTrCP
. In this way, RIPK1 was proposed to 
promote cell survival by allowing activation of 
the canonical NF-!B. Consistent with this 
model, gene deletion of RIPK1 sensitises cells to 
killing by TNF in combination with low doses of 
cycloheximide (2). However, we have recently 
shown that RIPK1 is not essential for activation 
of canonical p65/RelA NF-!B in response to 
TNF, but plays a redundant role (1). This 
suggests that the survival effect of RIPK1 in 
response to TNF is mediated by some other 
mechanism.  
Like RIPK1
-/-
 cells, those deficient for TRAF2 
are also more likely to die than wild type MEFs 
when treated with low doses of cycloheximide 
and TNF. This sensitisation was shown to be due 
to loss of function of the RING domain of 
TRAF2 (9). The fact that RIPK1 has been 
shown to interact directly with TRAF2 raised the 
possibility that they act in concert to inhibit cell 
death in response to TNF, but to date this has not 
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been confirmed, and the mechanism has not 
been elucidated (10).  
We reasoned that the ability of TRAF2 and 
RIPK1 to promote survival of TNF-treated cells 
might be related. To test this hypothesis we 
compared TRAF2
-/-
 and RIPK1
-/-
 gene deleted 
cells. Here we show that RIPK1 prevents 
activation of non-canonical NF-!B in response 
to TNF by protecting TRAF2 and cIAP1 from 
degradation. In both RIPK1
-/-
 and TRAF2
-/-
 
MEFs, cFLIPL is destabilised and rapidly 
degraded when TNF is added. In contrast, the 
cleaved form of cFLIP, p43cFLIP, remains 
stable, and is able to protect cells unless 
transcription or translation are inhibited.  
Materials and Methods 
Cell lines 
Wild-type and knockout MEFs were generated 
from E15 embryos in accordance with standard 
procedures and were infected with SV40T 
expressing lentivirus. All cell lines were 
maintained at 37˚C, 10% CO2 in DMEM 
supplemented with 10% FBS, penicillin, 
streptamycin and L-glutamine and passaged 
twice weekly. RIPK
+/- 
mice were a kind gift from 
Michelle Kelliher and TNFR1
-/-
 mice were a gift 
from Heinrich Korner. Thymocytes were 
isolated from timed matings as previously 
described (1). To generate murine keratinocytes 
the skin of E19 embryos was incubated 
overnight in 2.1U/mL dispase II (Roche) and 
gentamicin supplemented keratinocyte serum 
free media (KSFM; Invitrogen). The epidermis 
was then separated from the dermis and 
trypsinised to isolate epidermal keratinocytes 
which were cultured in KSFM. 
 
Death Assays  
Cells were seeded on 12 well tissue culture 
plates at approximately 50 percent confluency 
and were allowed to adhere for 16-20 hrs. 
Human Fc-TNF (100ng/ml), or CHX (250ng/ml) 
were added to cells for 24 hrs and cell death 
measured by PI staining and flow cytometry. In 
each sample 10,000 events were measured, and 
the survival (% PI negative cells) quantified.  
 
Nuclear Fractionation 
MEFs were treated with TNF for the indicated 
times and then cells were harvested and extracts 
made using the NE-PER
® 
Nuclear and!
$%&'()*+,-.! /0&1*.&-'2! 3-&! 45671,'!
+.-72&-8-.9! *+! (71!,*2:8*.&:171+! -2+&1:.&-'2+;!
<1*.&-'2!=717!*2*)%+7>!?%!=7+&712!?)'&; 
 
Western Blotting   
Cells were treated with 100 ng/ml of Fc-TNF  or 
recombinant mmTNF for the times indicated. 
MG132, necrostatin, NH4Cl and chloroquine 
were added 1 hour prior to TNF addition. To 
remove them, cells were treated with trypsin and 
washed in ice-cold PBS, and lysed in DISC 
buffer (1% Triton X-100, 10% glycerol, 150 
mM NaCl, 20 mM Tris pH 7.5, 2 mM EDTA, 
Roche complete protease inhibitor cocktail, 5 
µM NEM) on ice. Cell lysates were spun at 
14,000 g for 10 min and the soluble material 
retained. For insoluble fractions, the pellet was 
resuspended in 1% SDS with 10 mM TRIS pH 
7.4 and boiled for 10 min. Samples were then 
sonicated briefly to shear DNA, and then boiled 
for 5 min with sample loading buffer. Samples 
were separated on 4-12% polyacrylamide gels 
(Invitrogen), and transferred to nitrocellulose 
membranes for antibody detection. All 
membrane blocking steps and antibody dilutions 
were performed with 5% skim milk in PBS 
containing 0.1% Tween 20 (PBS-T), and 
washing steps performed with PBS-T. After 
incubating with HRP-coupled secondary 
antibodies, Western blots were visualized by 
ECL (Amersham, UK and Millipore). 
 
 
Reagents and Antibodies   
The primary antibodies used were anti-!-actin 
(A-1978, Sigma), anti-RIPK1 (610458, BD 
Transduction Laboratories),  anti-cFLIP (XA-
1008, ProScience), anti-TRAF2 (sc-876, Santa 
Cruz), anti-cIAP1 (in house), anti-PARP (9542, 
Cell Signaling Technology), anti-Caspase-8 
(Gift from Lorraine O’Reilly, Walter and Eliza 
Hall Institute), anti-NIK (4994, Cell Signaling 
Technology), anti-NF-!B2 P100 (4882, Cell 
Signaling Technology), anti-Lamin A/C (#@AB"C!
D*2&*! $1:E9. Proteasome and lysosomal 
inhibitors MG132 (Saphire Biosciences) and 
Chloroquine (Sigma). RIPK1 kinase inhibitor 
Necrostatin-1 (Sigma), Fc-TNF and FC-FasL (in 
house), Iso Leu TRAIL (gift from Christoph 
Emmerich), soluble mmTNF (315001a, 
peprotech), Compound A (TetraLogic 
Pharmaceuticals). 
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Results 
In response to TNF, TRAF2 and cIAP1 
remain stable in wild-type cells but are 
degraded in RIPK1
-/-
 MEFs. 
Like RIPK1
-/-
 mouse embryonic fibroblasts 
(MEFs), those derived from TRAF2
-/-
 mice have 
increased sensitivity to induction of apoptosis by 
TNF (11). It has been reported that cFLIP levels 
decline when TRAF2
-/-
 MEFs are treated with 
TNF, whereas they remain stable in wild type 
MEFs (3). To determine whether a decline in 
cFLIP following TNF treatment might also 
explain the increased sensitivity of RIPK1
-/-
 
MEFs to TNF, RIPK1
-/-
 and TRAF2
-/-
 MEFs 
were treated with TNF for 1 hour, and Western 
analysis was performed to determine levels of 
TRAF2, cIAP1 and cFLIP  (Fig. 1A). Although 
resting levels of cFLIPL were the same in all cell 
genotypes, when TNF was added cFLIPL was 
lost in both RIPK1
-/-
 and TRAF2
-/-
 MEFs, but not 
wild type MEFs.  In addition to the loss of 
cFLIPL in the RIPK1
-/-
 and TRAF2
-/-
 MEFs, 
there was also a striking decrease in the levels of 
TRAF2 and cIAP1 in TNF-treated RIPK1
-/-
 
MEFs (Fig. 1A lane 4). TRAF2 loss was 
confirmed in multiple cell lines derived from 
independent embryos (Supp. Fig 1).  
TRAF2 and cIAP1 form a complex with TRAF3 
and cooperate in ubiquitylation and degradation 
of NIK (NF-!B Inducing Kinase) (12,13). When 
TRAF3 levels were examined under the same 
treatments, there was no observable degradation 
(data not shown). 
Because treatment with the TNF related cytokine 
TWEAK or TNF itself causes re-localization of 
TRAF2 and cIAP1 (14-17), we wondered 
whether their re-localization would be affected 
by deletion of RIPK1. To test this, we first 
treated RIPK1
-/-
 MEFs with TNF and lysed them 
in Death Inducing Signalling Complex (DISC) 
lysis buffer and separated detergent soluble and 
insoluble fractions. These were then analysed by 
Western blot for levels of cIAP1 and TRAF2 
(Fig. 1B). Unlike normal MEFs, in TNF treated 
RIPK1
-/- 
cells the majority of TRAF2 and cIAP1 
disappeared from the soluble fraction, and 
simultaneously increased in the insoluble 
fraction within 15 minutes (Fig. 1B). The 
amount of TRAF2 in the insoluble fraction 
subsequently decreased. Interestingly, in the 
insoluble fraction TRAF2 appeared to be a 
doublet, with one form migrating more slowly, 
and the other more rapidly than TRAF2 in the 
soluble fractions. 
Like TRAF2, cIAP1 was rapidly lost from the 
soluble fraction in RIPK1
-/-
 cells, but unlike 
TRAF2, there was no apparent transfer of cIAP1 
from the soluble to the insoluble fraction at 15 
minutes. Instead, cIAP1 seemed to be degraded 
before it could be detected in the insoluble 
fraction (Fig. 1B). The speed of this trafficking 
and degradation was more rapid than that 
observed following treatment with TWEAK, 
which requires hours to cause degradation of 
TRAF2 and cIAP1 (14,18).  
We next pre-treated the MEFs with either the 
proteasome inhibitor MG132, or the lysosomal 
inhibitors NH4Cl and chloroquine, and exposed 
them to TNF for one hour. Cells were then lysed 
in DISC buffer and separated into soluble and 
insoluble fractions and analysed by Western 
blot. The proteasome inhibitor MG132 was able 
to reduce degradation of TRAF2 and cIAP1 
(Fig. 1C lanes 3, 8). Both of the lysosomal 
inhibitors provided some protection to TRAF2 in 
the insoluble fraction, but less for cIAP1 (Fig. 
1C lanes 4, 5, 9, 10). cIAP1 accumulated in the 
insoluble fraction of MG132 treated cells, 
indicating that cIAP1 is recruited to the 
insoluble fraction prior to degradation, as occurs 
with TRAF2. Therefore in the absence of 
RIPK1, addition of TNF triggers degradation of 
both TRAF2 and cIAP1 by the proteasome. 
Partial blockage of degradation of TRAF2 and 
cIAP1 by lysomal inhibitors may suggest, at 
least in part, that degradation occurs in 
lysosomes too. 
The cIAP1 that accumulated in the insoluble 
fraction with MG132 treatment appeared to be 
modified in a pattern consistent with 
ubiquitylation. To confirm the modification of 
TRAF2 and cIAP1, RIPK1
-/-
 MEFs were treated 
with TNF for 0, 5 and 15 mins and cells lysed in 
DISC or SDS buffer  (Fig.1D). There is a clear 
laddering/smearing of both TRAF2 and cIAP1 
after TNF treatment. While not conclusive, this 
is suggestive of ubiquitylation.  
The E3 ligases cIAP1 and cIAP2 are able to 
ubiquitylate both themselves and TRAF2 (19-
21). TRAF2 interacts with cIAPs via specific 
cIAP interacting motif (3). To determine if 
cIAPs were responsible for the TNF-induced 
degradation of TRAF2 and cIAP1, wild type and 
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RIPK1
-/-
 MEFs were pre-treated with the IAP 
antagonist compound A for 1 hour, to degrade 
cIAPs, before the addition of TNF. Because pre-
treatment of RIPK1
-/-
 MEFs with compound A 
had no effect on the loss of TRAF2, cIAPs are 
not required for TNF-induced TRAF2 
degradation (Fig. 1E).  
We were unable to confirm that reconstitution of 
RIPK1 in the RIPK1
-/-
 MEFs reversed this 
phenotype as we consistently find that 
exogenous expression of RIPK1 in MEFs causes 
apoptotic death, even in RIPK1
-/-
 cells (data not 
shown). 
TNF-induced TRAF2 and cIAP1 degradation 
occurs in multiple RIPK1
-/-
 cell types. 
The tissues that are most affected by deletion of 
RIPK1 in mice are the thymus and spleen (2). 
To confirm that degradation of TRAF2 and 
cIAP1 occurs in primary cell types, thymocytes 
were taken from E19 embryos from RIPK1+/- 
timed matings and treated with TNF for 1 hour.. 
TRAF2 and cIAP1 were both degraded in 
RIPK1
-/-
 thymocytes after TNF treatment (Fig. 
2A, lanes 5-6 and 9-18), while in thymocytes 
from RIPK1
+/-
 embryos, no degradation was 
observed.  While some variation in the degree of 
TRAF2 and cIAP1 degradation can be seen, it is 
clear that there is degradation of either TRAF2 
or cIAP1 in all RIPK1
-/-
 thymocytes in response 
to TNF. 
In addition to thymocytes, primary keratinocytes 
were generated from timed matings of RIPK1
+/-
 
mice. The keratinocytes were treated with TNF 
and the levels of cIAP1 and TRAF2 analysed by 
western blot (Fig. 2B). In the wild type embryos 
no TRAF2 or cIAP1 degradation was seen. In 
contrast there was a reduction in the levels of 
both cIAP1 and TRAF2 in the RIPK1
-/-
 
keratinocytes treated with TNF, further 
confirming this phenotype in multiple primary 
cell lineages. 
To determine whether TNF would also cause 
loss of TRAF2 in the absence of RIPK1 in 
human cancer lines D645 (glioma) and HT29 
(colon cancer) by either Geldanamycin treatment 
or RIPK1 shRNA expression. Geldanamycin has 
been shown to induce RIPK1 degradation (22). 
With either approach of RIPK1 depletion, there 
is a clear loss of TRAF2 and cIAP1 after TNF 
treatment confirming that RIPK1 protects 
TRAF2 and cIAP1 from TNF-induced 
degradation in human cells as well (Fig. 2C & 
D). 
 
Signals leading to degradation of TRAF2 and 
cIAP1 come from TNFR1 and not TNFR2.  
TNF can ligate both TNFR1 and TNFR2. 
TNFR2 signalling has been reported to lead to 
degradation of TRAF2 and subsequent 
activation of non-canonical NF-!B (20,23). 
TNFR2 has a higher affinity for the membrane 
bound form of TNF (24). The Fc-TNF fusion 
protein that we used is thought to closely mimic 
the membrane bound form of TNF (24). Thus 
we wondered if the degradation of TRAF2 and 
cIAP1 seen in RIPK1
-/-
 MEFs may be due to Fc-
TNF ligand causing activation of TNFR2 
receptors.  
To determine wether TNFR1 or TNFR2 was the 
relevant receptor in these experiments, wild type 
and RIPK1
-/-
 MEFs were treated with soluble 
mouse TNF for 1 hour. Soluble TNF ligand is 
unable to trigger TNFR2 mediated TRAF2 
degradation (23). Despite this, there was a clear 
loss of TRAF2 in the RIPK1
-/-
 MEFs, consistent 
with the notion that TNFR1 signalling caused 
TRAF2 and cIAP1 degradation (Fig. 3A). 
However, because the degree of degradation 
appeared to be less than with Fc-TNF, we 
treated TNFR1
-/-
 RIPK1
-/-
 DKO MEFs with the 
Fc-TNF ligand and assessed the degradation of 
TRAF2 and cIAP1. In the absence of both 
TNFR1 and RIPK1 there was significantly less 
degradation of TRAF2 and cIAP1 (Fig. 3B), 
confirming that TNFR1 is the main receptor 
required for TNF to trigger degradation of 
TRAF2 and cIAP1 in RIPK1
-/-
 MEFs. 
While the role of RIPK1 in TNFR1 signalling 
has been extensively studied, its role in 
signalling from other TNF receptor family 
members is less clear. To determine if the 
absence of RIPK1 would lead to degradation of 
TRAF2 after ligation of other TNFSFR 
members, we looked at both CD95 and TRAIL 
receptor signalling in RIPK1
-/-
 MEFs, because  
both CD95 and TRAIL receptors have been 
reported to recruit RIPK1 and TRAF2, and both 
have a death domain (25-27). Despite their 
similar signalling mechanisms, neither ligand 
induced TRAF2 degradation in RIPK1
-/-
 MEFs 
(Fig. 3C).  
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The kinase activity of RIPK1 is not required 
to prevent TRAF2 and cIAP1 degradation. 
In order to determine if the kinase activity of 
RIPK1 was necessary to protect TRAF2 and 
cIAP1 from TNF induced degradation, wild type 
and RIPK1
-/-
 MEFs were pre-treated with the 
RIPK1 specific kinase inhibitor necrostatin (28) 
at concentrations shown to inhibit RIPK1 
dependant cell death ((29) and supp Fig. 2). The 
MEFs were then exposed to TNF or TNF and 
cycloheximide for 1 hour, and levels of TRAF2 
and cIAP1 were analysed by Western blot. 
Levels of TRAF2 were unaffected by addition of 
necrostatin, either in the presence or absence of 
TNF (Fig. 4A lane 4 and lanes 5-8).  
Wild type and RIPK1
-/-
 cells pre-treated with 
necrostatin were also treated with TNF and TNF 
plus low dose cycloheximide for 24 hours, and 
viability was assessed by propidium iodide (PI) 
exclusion using flow cytometry. As well as 
having no effect on TRAF2 degradation, 
necrostatin did not alter the sensitivity of wild 
type MEFs to apoptosis triggered by TNF (Fig. 
4B). The lack of requirement for the kinase 
activity of RIPK1 suggests that RIPK1 may be 
acting to protect TRAF2 and cIAP1 via a 
physical or interaction based mechanism, rather 
than by phosphorylating a substrate.   
TNF induces activation of non-canonical NF-
!B in RIPK1
-/-
 MEFs. 
Although transformed RIPK1
-/-
 B-cells have 
impaired activation of NF-"B in response to 
TNF (2), we have recently shown that RIPK1-/- 
MEFs can activate canonical NF-!B normally in 
response to TNF (1). On the other hand, loss of 
TRAF2 or cIAPs leads to activation of non-
canonical NF-!B, even in cells that have not 
been treated with cytokine (13,21,30-32). The 
loss of TRAF2 and cIAP1 seen in TNF-treated 
RIPK1
-/-
 MEFs suggested that there might be an 
induction of non-canonical NF-!B in addition to 
the canonical NF-!B response. To test this, both 
wild type and RIPK1
-/-
 MEFs were treated with 
TNF for various times, and lysates were 
analysed for markers of non-canonical NF-!B 
activation, namely degradation of p100 and 
production of p52. Wild type MEFs were also 
treated with compound A to degrade cIAPs as a 
positive control (31).  
Western blot assays showed that steady state 
levels of non-canonical NF-!B and NIK were 
slightly higher in RIPK1
-/-
 MEFs compared to 
wild type MEFs (Fig. 5A, lanes 1 and 7). 
However, following addition of TNF there was a 
strong and sustained activation of non-canonical 
NF-!B with processing of p100 to p52 and 
stabilisation of NF-!B inducing kinase (NIK) 
(Fig. 5A lanes 7-12). Furthermore, the increase 
in NIK levels and processing of p100 to p52 in 
TNF treated RIPK1
-/-
 MEFs was similar to that 
caused by depletion of cIAPs by smac-mimetic 
compound in wild type MEFs (Fig. 5A lanes 13-
18, and (31)).  
Supporting the idea that the increase in NIK 
levels is a consequence of TRAF2 and cIAP1 
degradation, there was a strong correlation 
between the loss of TRAF2 and cIAP1 and the 
subsequent stabilization of NIK and processing 
of p100 in response to TNF stimulation. Over 24 
hours, TRAF2 and cIAP1 levels began to 
recover, and there was a concomitant decrease in 
the levels of NIK (Fig. 5A lanes 7-12). 
To confirm that NIK stabilisation resulted in 
induction of non-canonical NF-!B signalling, 
the nuclear translocation of p52 was assessed. In 
RIPK1
-/-
 MEFs treated with TNF, the levels of 
nuclear p52 increase with similar kinetics to 
those in wild type cells treated with the IAP 
antagonist compound A (Fig. 5B, lanes 9-16 and 
17-24). Correspondingly, wild type cells treated 
with TNF showed no significant increase in 
nuclear p52 (Fig. 5B lanes 1-8). 
 
TRAF2 degradation is responsible for RIPK1
-
/-
 sensitivity to TNF.  
If the loss of cIAP1 and TRAF2 were 
responsible for the sensitisation of RIPK1
-/-
 
MEFs to killing by TNF plus low doses of CHX, 
we reasoned that because cIAP1 and TRAF2 
levels partially rebounded after several hours of 
TNF treatment (Fig. 5, lanes 8-12), addition of 
CHX at these later time points might not result 
in as much death. To test this, wild type, RIPK1
-
/-
 and TRAF2
-/-
 MEFs were treated with TNF, 
and low doses of CHX were added immediately, 
4 hours or 8 hours afterwards. Cells were then 
analysed for PI uptake by flow cytometry. In 
RIPK1
-/-
 MEFs, addition of CHX 4 and 8 hours 
after TNF" addition caused less cell death 
compared to immediate addition of CHX (Fig. 
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6). In contrast, TRAF2
-/-
 MEFs showed no 
decrease in sensitivity to TNF when CHX was 
added at later time points, suggesting that loss of 
TRAF2 is the key step in sensitizing RIPK1
-/-
 
MEFs to TNF. 
 
RIPK1
-/-
 and TRAF2
-/-
 MEFs show activation 
of caspase-8 following TNF treatment. 
While RIPK1
-/- 
MEFs treated with TNF activate 
NF-"B at the same rate as wild type MEFs (1), 
RIPK1
-/- 
MEFs are nonetheless much more likely 
to die when treated with TNF plus low dose 
cycloheximide (Figure 5A; (1,2)). In this respect 
RIPK1
-/-
 MEFs resemble TRAF2 knock-out 
MEFs, which are also much more sensitive to 
TNF and low dose cycloheximide than to TNF 
alone (11). TNF induced apoptosis is mediated 
by caspase-8. To examine caspase-8 activation 
in RIPK1
-/-
 and TRAF2
-/-
 MEFs, cells were 
treated with TNF or TNF plus cycloheximide for 
6 hours. Lysates were analysed for cleavage of 
caspase-8 and PARP, a caspase-3 substrate. In 
RIPK1
-/-
 and TRAF2
-/-
 MEFs treated with TNF, 
there was cleavage of caspase-8 to its p43 form 
(Fig. 7A lanes 5 & 11). Addition of CHX in 
combination with TNF resulted in increased 
cleavage of PARP and caspase-8 to its p43 form 
in both genotypes (Fig. 7A, lanes 6 & 12), and 
the generation of the p18 form of caspase-8 can 
be seen in the RIPK1
-/-
 MEFs (Fig. 6B, lane 12). 
In both genotypes, cleavage of PARP was seen, 
suggesting activation of caspase-3. In contrast, 
in wild type cells, neither TNF nor TNF plus 
CHX resulted in significant processing or 
cleavage or caspase-8 or PARP.  
 
TNF mediated transcription of a pro-survival 
protein protects RIPK1
-/-
 and TRAF2
-/-
 MEFs 
from death. 
It is commonly inferred that CHX sensitizes 
cells to TNF by preventing translation of pro-
survival proteins such as cFLIP, which are 
otherwise induced by NF-!B signals from 
TNFR1 (33). The fact that the low doses of 
CHX that can sensitise both TRAF2
-/-
 and 
RIPK1
-/-
 cells to killing by TNF do not allow 
TNF to kill wild type cells, whereas high doses 
of CHX do sensitise wild type cells to TNF, 
suggests that low doses of CHX do not block 
translation completely.  
To test whether inhibition of transcription could 
sensitise cells to TNF, just as CHX could by 
inhibiting translation we treated cells with the 
transcription inhibitor actinomycin D. If the 
effect of low doses of CHX were due to a result 
of inhibition of translation of a transcriptionally 
induced pro-survival protein, then the same 
effect should be seen with inhibition of 
transcription. Indeed, this appears to be the case, 
because inhibition of transcription with 
actinomycin D allowed TNF to induce death of 
RIPK1
-/-
 and TRAF2
-/-
MEFs with very similar 
kinetics to those caused by inhibition of 
translation with CHX (Fig. 7B). This supports 
the idea that there is a transcriptionally up-
regulated protein(s) protecting RIPK1
-/-
 and 
TRAF2
-/-
 MEFs from being killed by TNF alone.!
Furthermore, these observations would be 
consistent with a mechanism in which RIPK1 
protects the cells by stabilizing TRAF2, and 
TRAF2 is needed for the signals that up-regulate 
transcription of a gene for a cell death inhibitory 
protein.  
 
cFLIPL is destabilized in RIPK1
-/-
 and 
TRAF2
-/-
 MEFs. 
A key regulator of caspase-8 activation that is 
known to be transcriptionally controlled, and 
may be destabilised by TNF, is cFLIP 
(3,33,34). As seen in Fig. 1A, the levels of 
cFLIPL decline significantly within 1 hour of 
TNF treatment of RIPK1
-/-
 and TRAF2
-/-
 MEFs, 
and there is a concomitant appearance of 
p43cFLIP, the caspase-8 cleavage product of 
cFLIPL. The rapid loss of cFLIPL and 
appearance of a relatively small amount of 
p43cFLIP in TNF treated RIPK1
-/-
 and TRAF2
-/-
 
cells, suggests that there is both cleavage of 
cFLIPL by caspase-8, as well as a signal that 
targets cFLIPL for degradation. To examine this, 
wild type, RIPK1
-/-
 and TRAF2
-/-
 MEFs were 
treated with the proteasomal inhibitor MG132 
for 1 hour prior to treatment with TNF. Cells 
were lysed in DISC lysis buffer and probed for 
cFLIP. MG132 pre-treatment prevented loss of 
cFLIPL in both RIPK1
-/-
 and TRAF2
-/-
 MEFs, but 
had only a minor effect on the levels of 
p43cFLIP, even reducing it to some extent (Fig. 
8A, lanes 6 and 9). This indicates that, in the 
absence of RIPK1
-/-
 or TRAF2
-/-
, either TNF 
causes activation of an MG132-inhibitable 
process that degrades cFLIPL, or that cFLIPL is 
constantly being degraded by an MG132-
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inhibitable process, but RIPK1 and TRAF2 are 
needed to replenish it 
RIPK1
-/-
 MEFs are slightly more sensitive than 
wild type MEFs to treatment with TNF alone 
while TRAF2
-/-
 MEFs exhibit somewhat higher 
sensitivity (Fig. 6) (1,11). The rapid cleavage of 
cFLIPL to p43cFLIP, and equally rapid 
destabilisation of cFLIPL, suggests that 
p43cFLIP may be sufficient to prevent enough 
activation of caspase-8 to cause cell death. 
Inhibition of transcription or translation, even 
slightly, may be sufficient to tip the scales in 
favour of cell death by reducing the levels of 
p43cFLIP, thereby allowing further cleavage and 
activation of caspase-8. To examine the half-life 
of cFLIPL and p43cFLIP in the presence of low 
dose cycloheximide, wild type, RIPK1
-/-
, and 
TRAF2
-/-
 MEFs were treated with CHX, TNF, or 
both for various times, and levels of cFLIP were 
assessed by Western blot. As can be seen in Fig. 
8B, cFLIPL was cleaved to p43cFLIP and also 
degraded more rapidly in RIPK1
-/-
 and TRAF2
-/-
 
MEFs treated with TNF or TNF plus CHX (Fig. 
8B). p43cFLIP remained present over the three 
hour time course showing that it either has a 
longer half life, or that any newly translated 
cFLIPL was being rapidly cleaved and degraded 
at a rate that maintained p43cFLIP levels. In 
comparison, wild type cells showed no cFLIPL 
cleavage when treated with TNF alone, or TNF 
plus low dose CHX. Addition of CHX reduced 
the level of p43cFLIP and cFLIPL over time, 
coinciding with the onset of death and the 
appearance of cleaved caspase-8 at around four 
hours after addition of TNF plus CHX (Fig. 8B 
and Fig. 7B).  
Over-expression of cFLIPL can protect TRAF2
-/-
 
MEFs from killing by TNF (35). If loss of 
cFLIPL is the cause of death in RIPK1
-/-
 MEFs, 
exogenous expression of cFLIPL or p43cFLIP 
should be able to prevent caspase-8 activation 
and death. To confirm this in both TRAF2
-/-
 
MEFs and RIPK1
-/-
 MEFs, cells were infected 
with inducible lentiviral constructs expressing 
either cFLIPL or p43cFLIP. Cells were then left 
untreated or treated with TNF plus low dose 
CHX and assayed for cell death. Induction of 
either form of cFLIP was able to protect most of 
the cells of both genotypes from death caused by 
TNF plus low dose CHX. (Fig. 8C). This 
indicates that the mechanism of death triggered 
by TNF is capable of being inhibited by both 
cFLIPL and p43cFLIP. 
 
Discussion. 
Although RIPK1 can promote cell death in 
certain circumstances, it is clear that RIPK1 can 
also promote survival of TNF treated cells. For 
many years it was thought that this was due to a 
requirement for RIPK1 to activate canonical NF-
"B and induce pro-survival genes such as cFLIP 
and cIAPs. While RIPK1 ubiquitylation and 
recruitment of IKKs clearly plays a part in TNF 
induced NF-"B activation in some cell types, the 
finding that RIPK1 is not essential for TNF to 
activate canonical NF-"B in MEFs suggested 
some other function of RIPK1 is responsible for 
its pro-survival effects (1). Our finding that in 
the absence of RIPK1, addition of TNF caused 
rapid degradation of TRAF2, cIAP1 and cFLIPL 
now provides an additional mechanism to 
explain why RIPK1
-/-
 cells are highly sensitive to 
TNF plus low doses of cycloheximide, and why 
they share this phenotype with TRAF2
-/-
 cells.  
The fact that cIAP1 was rapidly degraded after 
TNF was added to the RIPK1
-/-
 MEFs raised the 
possibility that death of the cells was due to the 
absence of cIAP1 (21,31,36,37). However, we 
do not favour this notion, because previous 
experiments with cIAP1 gene deleted cells, or 
cells treated with an IAP antagonist that depletes 
cells of cIAP1, showed that killing by TNF 
could be blocked by the RIPK1 kinase inhibitor 
necrostatin or genetic deletion of RIPK1 (1,37) . 
These experiments are consistent with 
observations from Wang et al. that TNF can 
induce two differentially regulated caspase 8 
dependent pathways (37). In addition, there is 
no observable loss of cIAP1 in TRAF2
-/-
 MEFs 
treated with TNF (Fig. 1A.), yet TRAF2
-/-
 MEFs 
exhibit the same phenotype as RIPK1
-/-
 MEFs in 
response to TNF. 
Our results are consistent with a model in which 
TNF activates canonical NF-"B in wild type 
MEFs, but does not induce cell death, because 
RIPK1 is recruited to a complex associated with 
TNFR1, where it becomes ubiquitylated, 
allowing recruitment of further proteins. In this 
way, RIPK1 plays a non-essential role in 
activation of p65/RelA NF-"B, but also 
somehow protects TRAF2, cIAP1 and cFLIP 
from degradation (Fig.9A). These proteins 
prevent activation of caspase-8. In the presence 
of TNF plus low dose CHX, wild type MEFs 
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still survive, but those derived from RIPK1
-/-
 or 
TRAF2
-/-
 mice do not.  We believe this is 
because when TRAF2 is absent, cFLIPL is 
destabilised and activation of caspase 8 is no 
longer blocked (Fig. 9B). Addition of CHX is 
required for TNF to cause death of RIPK1
-/-
 or 
TRAF2
-/-
 MEFs due to the level of 
transcriptionally up-regulated production of 
cFLIPL and the rate of its degradation and 
cleavage being in equilibrium. When translation 
or transcription is inhibited, even at levels that 
have no adverse effects on wild type cells, then 
the amount of cFLIPL and p43cFLIP are reduced 
enough to allow further processing of caspase 8 
and death in response to TNF. Consistent with 
this model, we were able to detect minimal 
levels of cFLIPL in RIPK1
-/-
 MEFs treated with 
TNF alone, but cFLIPL was rapidly reduced to 
undetectable levels in cells treated with TNF 
plus low dose CHX (Fig. 9B). 
Observations suggesting that the RING domain 
of TRAF2 is important for its pro-survival 
function may provide clues to the mechanism of 
TRAF2s cytoprotective activity (1,3,9). While 
we do not yet know how RIPK1 prevents 
destabilization of TRAF2, experiments with the 
kinase inhibitor necrostatin show that RIPK1’s 
kinase activity is not required for its pro-survival 
activity. This is in marked contrast to RIPK1’s 
pro-death activity when caspases are blocked or 
IAP antagonists used in combination with TNF, 
which can be blocked with necrostatin or kinase 
domain mutation and hence does require its 
kinase activity (27,28,37-39). One possibility is 
that in complex I, RIPK1 prevents a ubiquitin E3 
ligase from access to TRAF2 and cIAP1. 
These results explain why RIPK1
-/-
 and TRAF2
-/-
 
MEFs respond in a similar way to TNF plus low 
dose CHX, and may also explain similarities in 
the phenotypes of RIPK1
-/-
 and TRAF2
-/-
 mice. 
Mice of either genotype exhibit early post-natal 
lethality with severe reduction in thymocyte and 
splenocyte populations (2,40). Several studies 
have shown that crossing TRAF2
-/-
 and TRAF3
-/-
 
mice, which both exhibit constitutive non-
canonical NF-"B, with IKK#/Nemo mutant Aly 
mice or NF-"B2
-/-
 mice protected them from 
death and rescued their lymphocyte populations 
(13,30,41).  Likewise, degradation of TRAF2 
and cIAP1 in RIPK1
-/-
 mice may be causing an 
NF-"B2 dependant death of lymphocytes.  
These new findings characterising the pro-
survival activity of RIPK1, highlight that far 
from simply being a scaffold protein in TNFR 
signalling, RIPK1 seems to be playing a key role 
in regulating receptor signalling in cooperation 
with TRAFs and cIAPs. Being able to separate 
the pro-survival functions of RIPK1 from its 
pro-death functions will surely help in 
understanding the exact role RIPK1 is playing in 
regulation of TNF receptor signalling. 
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Figure Legends 
Figure 1: TRAF2 and cIAP1 are degraded in RIPK1
-/-
 MEFs in repose to TNF. 
A. Wild type, RIPK1
-/-
 and TRAF2
-/-
 MEFs were treated with 100 ng/ml Fc-TNF for 1 hour and then 
lysed with DISC buffer. Proteins were analysed by Western blot for cIAP1, TRAF2, RIPK1 and 
cFLIP. B. Wild type and RIPK1
-/-
 MEFs were treated with 100 ng/ml Fc-TNF for 0, 15, 30 and 60 
min. Cells were then lysed in DISC lysis buffer and split into soluble and insoluble fractions. 25 mg 
of protein from both fractions was run on SDS-PAGE and analysed for levels of indicated proteins by 
Western blot. C. RIPK1
-/-
 MEFs were treated with either 10 #M MG132, 100 mM NH4Cl, or 200 
mM chloroquine for 1 hour followed by treatment with 100 ng/ml Fc-TNF for 1 hour.  DISC lysates 
were then separated into soluble and insoluble and levels of indicated proteins detected by Western 
blot. D. Wild type and RIPK1
-/-
 MEFs were treated with either 500 nM compound A or untreated for 
1 hour followed by addition of 100 ng/ml Fc-TNF for 1 hour. DISC lysates were made and the soluble 
and insoluble fraction was analysed for levels of cIAP1 and TRAF2 by Western blot.  
!"#$%&'()'*+,!('-./'01,23'-%&'/&#%-/&/'".'4%"5-%6'7"88$&8'7%&-7&/'9"7:'*;!<'
A. E19 embryos were taken and thymus was harvested. Keratinocytes were isolated from … Day old 
RIPK
-/-
 1 day old pups. Thymi were dispersed into single cell suspensions and half of each was left 
untreated while the other half was treated with 100 ng/ml Fc-TNF for 1 hr. Cells were lysed in DISC 
lysis buffer and analysed for TRAF2 and cIAP1 by Western blot. Genotypes were confirmed by 
Western blot and PCR. B. Primary keratinocytes were trated with 100 ng/ml Fc-TNF for 1 hr or 500 
nM Compound A as a positive control for cIAP1 degradation, followed by lysis in DISC buffer and 
proteins detected by western blot. C. D645 and HT29 cells were pretreated with 500nM 
Geldanamycin for 16hrs followed by treatment with 100 ng/ml Fc-TNF for 1 hour followed by lysis 
in DISC buffer and analysed for protein levels by western blot. D. HT29 cells were infected an 
lentiviral shRNA against RIPK1 or a control shRNA and cells were then treated with 100 ng/ml Fc-
TNF for 1 hour followed by lysis in DISC buffer and analysed for protein levels by western blot. 
Figure 3: TNFR1 mediates the degradative signal for TRAF2 and cIAP1. 
A. Wild type and RIPK1
-/-
 MEFs were left untreated or treated with 100 ng/ml soluble mmTNF for 1 
hour and DISC lysates analysed for the levels of TRAF2 and cIAP1. B. Wild type, RIPK1
-/-
 and 
RIPK1
-/-
 TNFR1
-/-
 double knockout MEFs were treated with 100 ng/ml Fc-TNF for 1 hour and levels 
of TRAF2 and cIAP1 were assessed. C. Wild type and RIPK1
-/-
 MEFs were treated with either 10 
ng/ml of FasL or 1 mg/ml of Iso Leu TRAIL for 1 hour and lysates were analysed for levels of 
TRAF2 and cIAP1. 
Figure 4: The kinase activity of RIPK1 is not required for protection of TRAF2 and cIAP1. 
A. Wild type and RIPK1
-/-
 MEFs were pre-treated with NEC-1 followed by treatment with 100 ng/ml 
Fc-TNF for 1 hour and lysed in DISC followed by detection of TRAF2 levels by Western blot. B. 
Wild type and RIPK1
-/-
 MEFs were treated with NEC-1 for 1 hour prior to treatment with 100 ng/ml 
Fc-TNF for 24 hours. Cells were isolated and stained with propidium iodide and analysed for uptake 
by flow cytometry. Error bars show SEM of at least three independent experiments. To control for 
NEC-1 activity, L929 cells  
Figure 5: TNF induces non-canonical NF-!B in RIPK1
-/-
 MEFs. 
A. Wild type and RIPK1
-/-
 MEFs were treated with 100 ng/ml Fc-TNF for the times shown. In 
parallel, wild type MEFs were also treated with 500 nM compound A for the same times. Cells were 
lysed in DISC buffer and analysed for the levels of NIK, cIAP1, and TRAF2, and processing of p100 
to p52. B. wildtype and RIPK1
-/-
 MEFs were treated with 100ng/ml of Fc-TNF for the indicated times 
followed by fractionation into cytosolic and nuclear fractions. Fractions were then analysed by 
western blot for the levels of p100/p52 and Lamin A/C and Hsp70 as a loading controls. 
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Figure 6: Loss of TRAF2 is responsible for the sensitivity of RIPK1
-/-
 MEFs to TNF.  
A. Wild type, RIPK1
-/-
 and TRAF2
-/-
 MEFs were left untreated or treated with 100 ng/ml Fc-TNF for 
24 hours. 250 ng/ml CHX was added immediately, 4 hours or 8 hours after TNF addition, and cells 
were analysed for viability by PI uptake using flow cytometry. 
Figure 7: RIPK1
-/-
 and TRAF2
-/-
 MEFs transcriptionally up-regulate a pro-survival protein, and 
show activation of caspase-8. 
A. Wild type, RIPK1
-/-
 and TRAF2
-/-
 MEFs were treated with either 100 ng/ml Fc-TNF for six hours 
or 100 ng/ml Fc-TNF plus 250 ng/ml of CHX for six hours. Cells were lysed in DISC buffer and 
cleavage of caspase-8 and PARP were analysed by Western blot. B. Wild type, RIPK1
-/-
 and TRAF2
-/-
 
MEFs were treated with either 250 ng/ml of CHX or 25 ng/ml of actinomycin D in combination with 
100 ng/ml Fc-TNF for 2 or 4 hours. As a control, cells were also treated for 24 hours with 100 ng/ml 
Fc-TNF, 250 ng/ml of CHX, and 25 ng/ml of actinomycin D alone. Cells were harvested and stained 
with PI followed by analysis by flow cytometry. Error bars show SEM of at least three independent 
experiments. 
Figure 8: cFLIPL is destabilised in RIPK1
-/-
 and TRAF2
-/-
 MEFs. 
A. Wild type, RIPK1
-/-
 and TRAF2
-/-
 MEFs were treated either with MG132 for 1 hour prior to 
treatment with 100 ng/ml Fc-TNF for 1 hour, or 100 ng/ml Fc-TNF for 1 hour alone. Cells were lysed 
in DISC buffer and levels of cFLIPL and p43cFLIP were detected by Western blot. B. Wild type, 
RIPK1
-/-
 and TRAF2
-/-
 MEFs were treated with either 100 ng/ml Fc-TNF, 250 ng/ml CHX or a 
combination of both for the indicated times. Levels of cFLIP and cLFIP-43 were detected by Western 
blot. C. Wild type, RIPK1
-/-
 and TRAF2
-/-
 MEFs were infected with 4HT inducible lentiviral 
constructs coding for cFLIPL or p43cFLIP. Constructs were either induced or not overnight and then 
treated with 100 ng/ml Fc-TNF for 24 hours. Cells were harvested and stained with PI and analysed 
for uptake by flow cytometry. Error bars represent SEM from at least three independent experiments. 
Figure 9: Model of pro-death and pro-survival functions of RIPK1. 
A. Wild type cells 1. TNF binding triggers assembly of complex I by recruitment of TRAFs and 
cIAPs, which results in p65/RelA NF-!B translocation to the nucleus. 2. cFLIPL is upregulated by 
NF-!B. 3. In the presence of RIPK1, TRAF2 and cIAP1 are stabilised (potentially by direct 
interaction with RIPK1, but it does not require RIPK1’s kinase activity) and TRAF2 mediates 
stabilisation of cFLIPL by an unknown mechanism. 4. cFLIPL binds to caspase-8, blocking its 
activation and preventing apoptosis. B. The pro-survival effect of RIPK1. 1. TNF binding triggers 
assembly of complex I by recruitment of TRAFs and cIAPs which results in NF-!B translocation to 
the nucleus. 2. cFLIPL is upregulated by NF-!B. 3. In the absence of RIPK1, cIAP1 and TRAF2 are 
degraded by a proteasomal/lysosomal mechanism. This also leads to NIK stabilization and p100 
processing (not shown), and translocation of p52/RelB dimers to the nucleus 4. Loss of TRAF2 leads 
to destabilisation of cFLIPL, the majority of which is degraded by a proteasomal mechanism. A 
proportion of cFLIPL interacts with caspase-8 and is cleaved to p43cFLIP, thereby blocking full 
caspase-8 activation. 5. Partial inhibition of transcription or translation reduces levels of cFLIPL and 
p43cFLIP allowing caspase-8 activation, resulting in apoptosis. 
 
 
!
!
!
!
 at W
alter & Eliza Hall Institute of M
edical Research (CAUL), on March 30, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
Figure 1
6030150 TNF6030150
TRAF2
cIAP1
Soluble
6030150 6030150
Insoluble
β-Actin
B.
Wild type RIPK1-/-Wild type RIPK1-/-
45
35
66
66
1 2 3 4 5 6 7 8 9 10 11 12 13 14 1516
13
35
RIPK1
cIAP1
cFLIPL
p43cFLIP
TRAF2
β−Actin
TNF - + - + - +
-
-
66
45
66
66
45
66
45
Wi
ld t
ype
RIP
K1
-/-
TR
AF
2
-/-A.
1 2 3 4 5 6
C.
TNFα
MG132
cIAP1
++- ++ ++- ++
NH4ClChlQ+
+
++
+
+- - - - - - - -
-- --
- - - -
-
-
-
- -
-
-
-
InsolubleSoluble
TRAF2
66
45
66
β−Actin45
35
1 2 3 4 5 6 7 8 9 10
+--
++- TNF
CmpA
TRAF2
cIAP1
β-Actin
+
-
+--
++-
+
-
45
35
66
66
45
Wild type RIPK1-/-
1 2 3 4 5 6 7 8
E.
D.
0 5 15 0 5 15 0 5 15 0 5 15
Wild type RIPK1-/- RIPK1-/- RIPK1-/-
1 2 3 4 5 6 7 8 9 10 11 12
cIAP1
TRAF2
β−Actin
0 5 15 0 5 15 0 5 15 0 5 15
Wild type RIPK1-/- RIPK1-/- RIPK1-/-
Soluble Insoluble
13 14 15 16 17 18 19 20 21 22 23 24
β−Actin
66
45
35
45
35
66
45
45
35
*
 at W
alter & Eliza Hall Institute of M
edical Research (CAUL), on March 30, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
Figure 2 14
TNF
RIPK1 shRNA
Ctrl. shRNA
TRAF2
cIAP1
RIPK1
β−Actin
D.
1 2 3 4
TRAF2
cIAP1
A.
RIPK1
β−Actin
TNF
Genotype
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
- +- +- +- +- + - +
-/-
- + - + - +
*
66
45
66
-/- -/- -/--/--/-
66
+/-+/-+/-
TRAF2
cIAP1
RIPK1
β−Actin
GA
TNF
1 2 3 4 5 6 7 8
D645 HT29C.
116
66
66
45
66
45
35
- +- + - +- +
+ +- - + +- -
- +- +
+ +- -
- -+ +
45
35
66
66
45
116
66
66
45
35
B.
TNF
Genotype
CmpA
cIAP1
β-Actin
TRAF2
66 RIPK1
- + +
+/+ -/-
- + +
- - +- - +
*
66
 at W
alter & Eliza Hall Institute of M
edical Research (CAUL), on March 30, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
cIAP1
Figure 3
+- TNF+-
RIP
K1
-/-
TRAF2
66
45
A.
β-Actin45
35
+- TNF+-
Wi
ld t
ype
RIP
K1
-/-
+-
RIP
K1
-/-
TN
FR
1
-/-
66
45
TRAF2
cIAP1
β-Actin
B.
66
45
35
66
Wi
ld t
ype
β-Actin
cIAP1
+
--
- -
+ -
-
FasL
TNF
TRAF2
TRAIL-- - +
66
45
66
45
35
C.
1 2 3 4 5 6
1 2 3 4
1 2 3 4
15
 at W
alter & Eliza Hall Institute of M
edical Research (CAUL), on March 30, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
Figure 4
0
10
20
30
40
50
60
70
80
90
100
Nec1
TNF
CHX
-
-
-
-
-
+
-
+
-
+
-
-
-
+
+
+
-
+
+
+
-
+
+
+
%
 P
I n
eg
at
ive
TNF
Nec1- + +-
+ - +-
RIPK1
TRAF2
66
45
35
A. B.
1 2 3 4
16
Wild type
RIPK1-/-
- + +-
+ - +-
RIPK1-/-Wild type
β-Actin
66
45
5 6 7 8
 at W
alter & Eliza Hall Institute of M
edical Research (CAUL), on March 30, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
NIK
p100
p52
RIPK1-/-
TRAF2
cIAP1
β-Actin
0 2 4 6 8 24
0 2 4 6 8 24
0 2 4 6 8 24 TNF[hours]------
------------ CmpA[hours]
*
116
66
45
116
66
45
66
45
35
Wild type Wild type
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Figure 5 17
A.
RIPK1-/-
0 1 3 6 ---
------------
Wild type Wild type
-
310 6
0 1 3 6 0 1 3 6 --- -
310 6----
0 1 3 6
CmpA[hours]
TNF[hours]
Cytosol Nuclear Cytosol Nuclear Cytosol Nuclear
HSP70
p100
p52
B.
1 2 3 4 5 6 7 8 9 10 1112 13 14 15 16 17 181920 21 22 23 24
Lamin A/C
116
66
45
116
66
45
66
45
 at W
alter & Eliza Hall Institute of M
edical Research (CAUL), on March 30, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
Figure 6 18
0
10
20
30
40
50
60
70
80
90
100
84
+
0--
+++-
%
 P
I n
eg
at
ive
Wild type
RIPK1-/-
TRAF2-/-
CHX (hrs post TNF)
TNF
 at W
alter & Eliza Hall Institute of M
edical Research (CAUL), on March 30, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
Figure 7
RIPK1-/-
TRAF2-/-UT TNF NEC CHX CHX
NEC
NEC
TNF
TNF
CHX
TNF
CHX
NEC
0
10
20
30
40
50
60
70
80
90
100
TNF
CHX
ActD
24842-2484224
24
-
-----24842-
-
-
2484224-------
Wild type
RIPK1-/-
TRAF2-/-
0
10
20
30
40
50
60
70
80
90
100
%
 P
I n
eg
at
ive
Wildtype
B.
19
A.
TNF
CHX
+
+
+
-
-
-
+
+
+
-
-
-
Wild type RIPK1-/-
+
+
+
-
-
-
+
+
+
-
-
-
Wild type TRAF2-/-
p55
PARP
β-Actin
p55
p43
p18
Caspase-8
short exp.
Caspase-8
long exp.
cleaved PARP
45
35
25
116
66
45
116
66
66
45
35
25
66
1 2 3 4 5 6 7 8 9 10 11 12
 at W
alter & Eliza Hall Institute of M
edical Research (CAUL), on March 30, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
Figure 8
B.
C.
0
10
20
30
40
50
60
70
80
90
100
Wild type
Untreated
p43cFLIP
cFLIPL
-
-
-
+
-
-
+
-
%
 P
I n
eg
at
ive
RIPK1-/-
-
-
-
+
-
-
+
-
TRAF2-/-
-
-
-
+
-
-
+
-
β-Actin
β-Actin
β-Actin
cFLIPL
cFLIPL
cFLIPL
p43cFLIP
p43cFLIP
p43cFLIP
W
ild
 ty
pe
RI
PK
1-
/-
TR
AF
2-
/-
-
- TNF [hours]
CHX [hours]
.5
-
1
-
2
-
3
- .5 1 2 3
- - - -
.5 1 2 3
.5 1 2 3
+-
++-
-+-
++-
-+-
++-
-
TNF
MG132
cFLIPL
p43cFLIP
β-Actin
Wild type RIPK1-/- TRAF2-/-
A.
45
35
45
35
1 2 3 4 5 7 8 9
1 2 3 4 6 7 8 9 10
6
11 12 13
TNF + CHX
45
35
45
35
45
35
45
35
45
35
45
35
5
20
 at W
alter & Eliza Hall Institute of M
edical Research (CAUL), on March 30, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
Figure 9
A.
NF-κB
B.
TRAF2
TRADD
TNF-R1
TNFα
cIAP1
cIAP2
Nucleus
survival APOPTOSIS
RIP1
cFLIPL
FADD
Caspase-8
TRAF1/?
RIP1?
TRADD
TNF-R1
TNFα
cIAP1
cIAP2
APOPTOSIS
cFLIPL
FADD
Caspase-8p43cFLIP
proteasomal
degradation
proteasomal/Lysosomal
degradation
TRAF2
TRAF1/?
Wild type
1.
2.
4.
RIPK1-/-
CHX/ActD
2.
3.
4.
5.
5. 4.
NF-κB
3.
P65/RelA
P52/RelB
Nucleus
survivalNF-κB
1.
 at W
alter & Eliza Hall Institute of M
edical Research (CAUL), on March 30, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
+- TNF+-
-/-+/+
+- +- +- +-
-/-+/+ -/-+/+ RIPK1 gentoype
#1 #2 #3
Supp. Figure 1
TRAF2
RIPK1
!-Actin
66
45
66
45
 at W
alter & Eliza Hall Institute of M
edical Research (CAUL), on March 30, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
010
20
30
40
50
60
70
80
90
100
%
 P
I 
n
e
g
a
ti
v
e
TNF+
+
-+-
NEC1+--
Supp. Figure 2
 at W
alter & Eliza Hall Institute of M
edical Research (CAUL), on March 30, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
Supplementary Figure 1: Comparison of multiple RIPK1
-/-
 MEF lines for TRAF2 
degradation. 
Three sets of wild type and isogenic RIPK1
-/-
 MEFs generated from three different litters 
were treated with 100 ng/ml Fc-TNF for 1 hour and then lysed with DISC buffer. Proteins 
were analysed by Western blot for TRAF2 and RIPK1.  
 
 
Supplementary Figure 2: Control to show Necrostatin activity. 
L929 cells were left untreated or pre-treated with necrostatin for 1 hour prior to addition of 
100ng/ml of Fc-TNF. Cells were then stained with propidium iodide and analysed for PI 
uptake by flow cytometry.  
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